<SEC-DOCUMENT>0001144204-19-014673.txt : 20190318
<SEC-HEADER>0001144204-19-014673.hdr.sgml : 20190318
<ACCEPTANCE-DATETIME>20190318171016
ACCESSION NUMBER:		0001144204-19-014673
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190318
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190318
DATE AS OF CHANGE:		20190318

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABEONA THERAPEUTICS INC.
		CENTRAL INDEX KEY:			0000318306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				830221517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15771
		FILM NUMBER:		19689115

	BUSINESS ADDRESS:	
		STREET 1:		3333 LEE PARKWAY
		STREET 2:		SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75219
		BUSINESS PHONE:		2149055100

	MAIL ADDRESS:	
		STREET 1:		3333 LEE PARKWAY
		STREET 2:		SUITE 600
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75219

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PLASMATECH BIOPHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20140922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ACCESS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19960209

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEMEX PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv516527_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(D) OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of report (Date of earliest event reported):
<B>March 18, 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B><U>ABEONA
THERAPEUTICS INC.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>Delaware</U></B></FONT></TD>
    <TD STYLE="width: 34%; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>001-15771</U></B></FONT></TD>
    <TD STYLE="width: 33%; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>83-0221517</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of</FONT><BR>
<FONT STYLE="font-size: 10pt">incorporation)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1330 Avenue of the Americas, 33rd Floor,
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>New York, NY 10019 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)
(Zip Code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>(646) 813-4712</U></B><BR>
(Registrant&rsquo;s telephone number, including area code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>N/A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see<I>&nbsp;</I>General
Instruction A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&uml;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&uml;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px"><FONT STYLE="font-size: 10pt"><B>Item 2.02.</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Results of Operations and Financial Condition.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 18, 2019,
Abeona Therapeutics Inc. issued a press release regarding its results of operations and financial condition for the fourth quarter
and fiscal year ended December 31, 2018 and forward-looking statements relating to full year 2019. A copy of the press release
is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information in
Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed &ldquo;filed&rdquo; for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), or otherwise subject to the
liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 96px"><FONT STYLE="font-size: 10pt"><B>Item 9.01</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Financial Statements and Exhibits.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(d) Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 86px; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt"><FONT STYLE="font-size: 10pt"><B><U>Exhibit No.</U></B></FONT></TD>
    <TD STYLE="width: 18px; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt"><FONT STYLE="font-size: 10pt"><B><U>Description</U></B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt"><A HREF="tv516527_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt">&nbsp;</TD>
    <TD STYLE="vertical-align: top; padding-top: 1.5pt; padding-right: 1.5pt; padding-left: 1.5pt"><A HREF="tv516527_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Press release dated March 18, 2019, entitled &ldquo;Abeona Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results.&rdquo;</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; border-bottom: black 1pt solid"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">Abeona Therapeutics Inc.</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">(Registrant)</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 30%">&nbsp;</TD>
    <TD STYLE="width: 12%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Neena M. Patil</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Neena M. Patil</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:&nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">General Counsel and Secretary </FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: March 18, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tv516527_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;<IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Abeona Therapeutics Reports Fourth Quarter
and Full Year 2018 Financial Results</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>On track to initiate Phase 3 VITAL&trade;
trial for treatment of RDEB in mid-2019; EB-101 to be manufactured in-house&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Manufacturing scaled to support AAV
based programs; GMP readiness expected 2H19</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Investor conference call on Tuesday,
March 19 at 10:00 a.m. ET</I>&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NEW YORK and CLEVELAND, Mar. 18, 2019
 &ndash; Abeona Therapeutics Inc. (Nasdaq: ABEO), a leading clinical-stage biopharmaceutical company developing novel cell and
gene therapies for serious diseases, today announced fourth quarter and full year 2018 financial results, and provided business
highlights. The Company will host a conference call on Tuesday, March 19 at 10:00 a.m. ET to discuss fourth quarter and full year
results, and to provide business highlights. Interested parties are invited to participate in the call by dialing 844-369-8770
(toll-free domestic) or 862-298-0840 (International) or via webcast at <FONT STYLE="color: Blue"><U>https://www.investornetwork.com/event/presentation/44847</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0; text-align: justify">&ldquo;The diligent work conducted
over the past nine months at our GMP manufacturing facility puts us on track to initiate the pivotal VITAL&trade; study evaluating
EB-101, our gene-corrected cell therapy for the treatment of recessive dystrophic epidermolysis bullosa, in mid-2019. We will produce
EB-101 at our Cleveland facility, which is an important milestone for Abeona. We are also advancing our manufacturing capabilities
to support our AAV gene therapy programs and expect to be at scale for GMP production in the second half of this year,&rdquo; said
Jo&atilde;o Siffert, M.D., Chief Executive Officer. &ldquo;On the lysosomal storage disease programs, we have stepped up efforts
to accelerate patient enrollment in the MPS III programs and recently implemented the protocols to enroll younger, higher functioning
patients.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0; text-align: justify">&ldquo;We believe that these important
steps have positioned Abeona for success in 2019 as we focus on advancing our clinical programs and developing our pipeline utilizing
novel AAV capsids,&rdquo; added Dr. Siffert.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">Fourth Quarter and Full Year Summary Financial Results:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cash, cash equivalents and marketable securities as of December
31, 2018 were $85.0 million, compared to $112.2 million as of September 30, 2018. The decrease in cash of $27.2 million was driven
primarily by the net cash used for operating activities of $17.0 million and cash used for the acquisition of the REGENXBIO license
of $10 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 19.45pt 0pt 0; text-align: justify">Revenues were $0.5 million
for the fourth quarter of 2018 compared with $0.2 million for the fourth quarter of 2017. The increased quarterly revenues resulted
from the recognition of Foundation grants that were announced during the fourth quarter of 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 19.45pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 19.5pt 0pt 0; text-align: justify">Net loss was $0.36 per share
for the fourth quarter of 2018, compared to $0.19 per share in the comparable period in 2017. For the twelve months ended December
31, 2018, net loss was $1.19 per share compared to $0.66 per share in the same period in 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 19.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 19.5pt 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 19.5pt 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 19.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Fourth Quarter and Recent Highlights:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">December 6, 2018: Provided lead program updates and unveiled data from AIM&trade; AAV vector platform
in cystic fibrosis and retinal diseases at R&amp;D Day</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">January 8, 2019: Appointed Christine Silverstein as Chief Financial Officer and Ed Carr as Chief
Accounting Officer</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">February 5-6, 2019: Presented new supportive data for novel gene therapies, including new proof-of-concept
data for the AIM vector platform at WORLD<I>Symposium</I></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 4.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">February 11, 2019: Appointed Jo&atilde;o Siffert, M.D. as Chief Executive Officer</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;As a fully-integrated organization,
Abeona is on the forefront of cell and gene therapy thanks to in-house manufacturing facilities, the AIM&trade; AAV vector platform,
and two programs in the clinic that have exclusive license to the AAV9 vector,&rdquo; said Steven H. Rouhandeh, Chairman of the
Board and Executive Chairman. &ldquo;Under Jo&atilde;o&rsquo;s leadership, the Company is focused on maximizing these end-to-end
capabilities as it prepares for important near-term milestones and beyond.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0; text-align: justify"><B>About Abeona Therapeutics </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0; text-align: justify">Abeona Therapeutics Inc. is a
clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases. Abeona's
lead programs include EB-101, its gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa, and ABO-102, a novel
AAV9 based gene therapy for Sanfilippo syndrome type A (MPS IIIA). The Company&rsquo;s portfolio of AAV9 based gene therapies
also features ABO-101 for Sanfilippo syndrome type B (MPS IIIB), and ABO-201 and ABO-202 for CLN3 disease and CLN1 disease, respectively.
Its preclinical assets include ABO-401, which uses the novel AIM&trade; AAV vector platform to address all mutations of cystic
fibrosis. Abeona has received numerous regulatory designations from the FDA and EMA for its pipeline candidates and is the only
company with Regenerative Medicine Advanced Therapy designation for two investigational therapies (EB-101 and ABO-102). For more
information, visit <FONT STYLE="color: Blue"><U>www.abeonatherapeutics.com</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0; text-align: justify"><B>Forward Looking Statement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 6pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>This press release contains certain statements that are forward-looking
within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended, and that involve risks and uncertainties. These statements include including but not limited to statements about
our existing cash and cash equivalents; our belief that we have a rich pipeline of products and product candidates; our belief
in our ability to continue to develop our novel AAV-vector gene therapy platform technology; our belief that EB-101 could potentially
benefit patients with recessive dystrophic epidermolysis bullosa (&ldquo;RDEB&rdquo;); our ability to initiate a Phase III clinical
trial for patients with RDEB and complete enrollment of patients into the trial; our belief that AAV treatment could potentially
benefit patients with MPS IIIA and B; our ability to add clinical sites and identify additional patients for our Phase I/II clinical
trial for patients with MPS IIIA and B; our ability to continue to secure and maintain regulatory designations for our product
candidates; our ability to develop manufacturing capability compliant with current good manufacturing practices for our product
candidates; our ability to manufacture gene therapy products and produce an adequate product supply to support clinical trials
and potentially future commercialization; our ability to secure timely regulatory review related to our clinical program; our belief
in the adequacy of the data from clinical trials in EB-101 and expansion cohort of our Phase I/II clinical trial in ABO-102 (AAV-SGSH)
for MPS IIIA, together with the data generated in the program to date, to support regulatory approvals; our intellectual property
position and our ability to obtain, maintain and enforce intellectual property protection and exclusivity for our proprietary assets.
We have attempted to identify forward looking statements by such terminology as &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;anticipate,&rdquo;
 &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; and similar expressions (as well as
other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify
forward-looking statements. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Actual results may differ materially from those indicated
by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not
limited to: continued interest in our rare disease portfolio, our ability to submit protocols and protocol amendments to regulatory
agencies, our ability to initiate and enroll patients in clinical trials, the adequacy of manufacturing capabilities, the impact
of competition, the ability to secure licenses or establish intellectual property rights for any technology that may be necessary
to continue to develop and commercialize our products, the ability to achieve or obtain necessary regulatory approvals, the impact
of changes in the financial markets and global economic conditions, risks associated with data analysis and reporting, and other
risks as may be detailed from time to time in the Company&rsquo;s annual reports on Form 10-K and quarterly reports on Form 10-Q
and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligation to revise
the forward-looking statements or update them to reflect events or circumstances occurring after the date of this presentation,
whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Investor Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Sofia Warner<BR>
Director, Investor Relations<BR>
Abeona Therapeutics<BR>
+1 (646) 813-4707<BR>
<FONT STYLE="color: #428BCA">swarner@abeonatherapeutics<U>.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Media Contact:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Scott Santiamo<BR>
Director, Corporate Communications<BR>
Abeona Therapeutics<BR>
+1 (718) 344-5843<BR>
<FONT STYLE="color: #428BCA"><U>ssantiamo@abeonatherapeutics.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>



<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] ,P# 2(  A$! Q$!_\0
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M35VG]_F=)_PC^BE<?V188]/LR?X5R^A6T.B?$O5-*L4$-C/9)=>0GW$DW8)
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M-=JL#@LP7KWQFGW=X+66U0H6^T3>4"#]T[2<_P#CM-O-/%[IWV1YG5OE(E4
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#?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
